Literature DB >> 2171331

Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease.

H Sakuraba1, A Oshima, Y Fukuhara, M Shimmoto, Y Nagao, D F Bishop, R J Desnick, Y Suzuki.   

Abstract

Efforts were directed to identify the specific mutations in the alpha-galactosidase A (alpha-Gal A) gene which cause Fabry disease in families of Japanese origin. By polymerase-chain-reaction-amplification of DNA from reverse-transcribed mRNA and genomic DNA, different point mutations were found in two unrelated Fabry hemizygotes. A hemizygote with classic disease manifestations and no detectable alpha-Gal A activity had a G-to-A transition in exon 1 (codon 44) which substituted a termination codon (TAG) for a tryptophan codon (TGG) and created an NheI restriction site. This point mutation would predict a truncated alpha-Gal A polypeptide, consistent with the observed absence of enzymatic activity and a classic Fabry phenotype. In an unrelated Japanese hemizygote who had an atypical clinical course characterized by late-onset cardiac involvement and significant residual alpha-Gal activity, a G-to-A transition in exon 6 (codon 301) resulted in the replacement of a glutamine for an arginine residue. This amino acid substitution apparently altered the properties of the enzyme such that sufficient enzymatic activity was retained to markedly alter the disease course. Identification of these mutations permitted accurate molecular heterozygote diagnosis in these families.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171331      PMCID: PMC1683686     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  18 in total

1.  FABRY'S DISEASE: CLASSIFICATION AS A SPHINGOLIPIDOSIS AND PARTIAL CHARACTERIZATION OF A NOVEL GLYCOLIPID.

Authors:  C C SWEELEY; B KLIONSKY
Journal:  J Biol Chem       Date:  1963-09       Impact factor: 5.157

2.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

3.  Ceramide trihexosidosis (fabry's disease) without skin lesions.

Authors:  J T Clarke; J Knaack; J C Crawhall; L S Wolfe
Journal:  N Engl J Med       Date:  1971-02-04       Impact factor: 91.245

4.  Fabry disease: molecular diagnosis of hemizygotes and heterozygotes.

Authors:  R J Desnick; H S Bernstein; K H Astrin; D F Bishop
Journal:  Enzyme       Date:  1987

5.  Residual activity of alpha-galactosidase A in Fabry's disease.

Authors:  G Romeo; M D'Urso; A Pisacane; E Blum; A De Falco; A Ruffilli
Journal:  Biochem Genet       Date:  1975-10       Impact factor: 1.890

6.  Pseudodeficiency of alpha-galactosidase A.

Authors:  G Bach; E Rosenmann; A Karni; T Cohen
Journal:  Clin Genet       Date:  1982-01       Impact factor: 4.438

7.  A strategy to reveal high-frequency RFLPs along the human X chromosome.

Authors:  J Aldridge; L Kunkel; G Bruns; U Tantravahi; M Lalande; T Brewster; E Moreau; M Wilson; W Bromley; T Roderick
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

8.  Fabry's disease with partially deficient hydrolysis of ceramide trihexoside.

Authors:  T Kobayashi; J Kira; N Shinnoh; I Goto; Y Kuroiwa
Journal:  J Neurol Sci       Date:  1985-02       Impact factor: 3.181

9.  Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme.

Authors:  D F Bishop; D H Calhoun; H S Bernstein; P Hantzopoulos; M Quinn; R J Desnick
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  43 in total

1.  Point mutations in the upstream region of the alpha-galactosidase A gene exon 6 in an atypical variant of Fabry disease.

Authors:  S Ishii; H Sakuraba; Y Suzuki
Journal:  Hum Genet       Date:  1992-04       Impact factor: 4.132

2.  Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes.

Authors:  Fumiko Matsuzawa; Sei-ichi Aikawa; Hirofumi Doi; Toshika Okumiya; Hitoshi Sakuraba
Journal:  Hum Genet       Date:  2005-05-28       Impact factor: 4.132

3.  Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene.

Authors:  I Redonnet-Vernhet; J K Ploos van Amstel; R P Jansen; R A Wevers; R Salvayre; T Levade
Journal:  J Med Genet       Date:  1996-08       Impact factor: 6.318

4.  Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype.

Authors:  Satoshi Ishii; Shoichiro Nakao; Reiko Minamikawa-Tachino; Robert J Desnick; Jian-Qiang Fan
Journal:  Am J Hum Genet       Date:  2002-02-04       Impact factor: 11.025

5.  Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes.

Authors:  C M Eng; G A Ashley; T S Burgert; A L Enriquez; M D'Souza; R J Desnick
Journal:  Mol Med       Date:  1997-03       Impact factor: 6.354

6.  A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted.

Authors:  N Miyamura; E Araki; K Matsuda; R Yoshimura; N Furukawa; K Tsuruzoe; T Shirotani; H Kishikawa; K Yamaguchi; M Shichiri
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

7.  Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease.

Authors:  Kevin Mills; Ashok Vellodi; Peter Morris; Donald Cooper; Michael Morris; Elisabeth Young; Bryan Winchester
Journal:  Eur J Pediatr       Date:  2004-10       Impact factor: 3.183

8.  Corrective effect on Fabry mice of yeast recombinant human alpha-galactosidase with N-linked sugar chains suitable for lysosomal delivery.

Authors:  Hitoshi Sakuraba; Yasunori Chiba; Masaharu Kotani; Ikuo Kawashima; Mai Ohsawa; Youichi Tajima; Yuki Takaoka; Yoshifumi Jigami; Hiroshi Takahashi; Yukihiko Hirai; Takashi Shimada; Yasuhiro Hashimoto; Kumiko Ishii; Toshihide Kobayashi; Kazuhiko Watabe; Tomoko Fukushige; Tamotsu Kanzaki
Journal:  J Hum Genet       Date:  2006-03-11       Impact factor: 3.172

9.  Alpha-galactosidase transgenic mouse: heterogeneous gene expression and posttranslational glycosylation in tissues.

Authors:  S Ishii; R Kase; H Sakuraba; C Taya; H Yonekawa; T Okumiya; Y Matsuda; K Mannen; M Takeshita; Y Suzuki
Journal:  Glycoconj J       Date:  1998-06       Impact factor: 2.916

10.  Human beta-galactosidase gene mutations in GM1-gangliosidosis: a common mutation among Japanese adult/chronic cases.

Authors:  K Yoshida; A Oshima; M Shimmoto; Y Fukuhara; H Sakuraba; N Yanagisawa; Y Suzuki
Journal:  Am J Hum Genet       Date:  1991-08       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.